Darunavir/cobicistat

Darunavir/cobicistat
Combination of
Darunavir	HIV protease inhibitor
Cobicistat	Cytochrome P450 (CYP3A) inhibitor
Clinical data
Trade names	Rezolsta, Prezcobix
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Prezcobix;
Pregnancy; category	AU: B2 [1]; US: N (Not classified yet) [1];
Routes of; administration	By mouth
ATC code	J05AR14 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Identifiers
CAS Number	206361-99-1 ; 1004316-88-4 ;
PubChem CID	57327017;
UNII	YO603Y8113; LW2E03M5PG ;
KEGG	D10832;
Chemical and physical data
Formula	C67H90N10O12S3
Molar mass	1323.70 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5;
	InChI InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1; Key:CXORHDVSJFELCV-HWDLLDTBSA-N;

Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[2] It contains darunavir and cobicistat.[2][3][4][2] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.[4][2]

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.[5][6][7][2][8]

References

"Cobicistat / darunavir (Prezcobix) Use During Pregnancy". Drugs.com. 25 June 2019. Retrieved 19 February 2020.
"Prezcobix- darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 6 June 2019. Retrieved 20 February 2020.
"Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services.
"Darunavir and Cobicistat (Professional Patient Advice)". Drugs.com. 16 September 2019. Retrieved 19 February 2020.
"Rezolsta EPAR". European Medicines Agency (EMA). Retrieved 4 April 2020.
"Antiretroviral drugs used in the treatment of HIV infection". U.S. Food and Drug Administration (FDA). 12 April 2018. Retrieved 19 February 2020.
"Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. 30 January 2015.
"Prezcobix (darunavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 June 2016. Retrieved 4 April 2020.

External links

"Cobicistat mixture with darunavir". Drug Information Portal. U.S. National Library of Medicine.
"Cobicistat". MedlinePlus.
"Darunavir". MedlinePlus.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Drugs.com_pregnancy-1] "Cobicistat / darunavir (Prezcobix) Use During Pregnancy". Drugs.com. 25 June 2019. Retrieved 19 February 2020.

[Prezcobix_FDA_label-2] "Prezcobix- darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 6 June 2019. Retrieved 20 February 2020.

[3] "Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services.

[Drugs.com-4] "Darunavir and Cobicistat (Professional Patient Advice)". Drugs.com. 16 September 2019. Retrieved 19 February 2020.

[5] "Rezolsta EPAR". European Medicines Agency (EMA). Retrieved 4 April 2020.

[6] "Antiretroviral drugs used in the treatment of HIV infection". U.S. Food and Drug Administration (FDA). 12 April 2018. Retrieved 19 February 2020.

[7] "Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. 30 January 2015.

[8] "Prezcobix (darunavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 June 2016. Retrieved 4 April 2020.